Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSD | A5PKW4 | 9/20 | 0.52 |
| ▸ | ARF6 | P62330 | 4/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19084663 | 0.91 | PSD (0.52) | PSDARF6PDE1APDE1BPDE4D | |
| SCHEMBL19084681 | 0.82 | PSD (0.51) | PSDARF6PDE4DPDE7APDE3A | |
| SCHEMBL19084516 | 0.82 | PSD (0.51) | PSDARF6PLAT | |
| SCHEMBL19084515 | 0.81 | PSD (0.49) | PSDARF6PLAT | |
| SCHEMBL19084690 | 0.79 | PSD (0.49) | PSDARF6PLAT | |
| SCHEMBL19084616 | 0.77 | PSD (0.52) | PSDARF6PLAT | |
| SCHEMBL19099435 | 0.76 | PSD (0.60) | PSDARF6PLAT | |
| SCHEMBL19084511 | 0.76 | PSD (0.57) | PSDARF6PLAT | |
| SCHEMBL19084604 | 0.75 | PSD (0.52) | PSDARF6PLAT | |
| SCHEMBL19084543 | 0.75 | PSD (0.58) | PSDARF6PLATEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849901-B2 | Arf6 inhibitors and methods of synthesis and use thereof | NAVIGEN, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | NAVIGEN, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | NAVIGEN, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | ARF6, ARF1, ARFIP2 | PSD 211/4885ARF6 1/4885NR4A2 3891/4885 |
| US-10849901-B2 | Arf6 inhibitors and methods of synthesis and use thereof | ARF6, ARF1, ARFIP2 | PSD 211/4885ARF6 1/4885NR4A2 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.